For example, CUDC-907 (a dual HDAC and PI3K inhibitor) caused dramatic regression of chemo-resistant multiple myeloma cell lines by upregulating natural killer group 2D (NKG2D) ligands and enhancing the ADCC effects in multiple myeloma cells [337]. Here, HDAC9 is linked to plasma cell myeloma.